CDK7 and retinoblastoma: MYCN-overexpressing retinoblastoma cells (MYCNO/E-cells) demonstrated remarkable sensitivity to MYC-targeting therapies, particularly transcriptional inhibitors such as THZ1 (a selective CDK7 inhibitor) and Flavopiridol (a broader-spectrum CDK inhibitor) [40,41].